Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zymeworks Inc (ZYME)
NASDAQ:ZYME
Zymeworks (ZYME) Stock Price & Analysis
458 Followers
ZYME Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.02 - $13.14
Previous Close$8.81
Volume920.90K
Average Volume (3M)622.35K
Market Cap
$627.94M
Enterprise Value$280.24M
Total Cash (Recent Filing)$374.33M
Total Debt (Recent Filing)$26.63M
Price to Earnings (P/E)-4.9
Beta0.70
Next Earnings
Aug 01, 2024EPS Estimate
-$0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.79
Shares Outstanding70,704,890
10 Day Avg. Volume758,851
30 Day Avg. Volume622,346
Standard Deviation0.16
R-Squared0.14
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.46
Price to Sales (P/S)8.20
Price to Cash Flow (P/CF)11.20
P/FCF Ratio12.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.69
Enterprise Value/Gross Profit3.69
Enterprise Value/Ebitda-2.75
Forecast
1Y Price Target
$13.93Price Target Upside50.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Zymeworks News
PremiumCompany Announcements
Zymeworks Touts Financial Health and R&D Progress
PremiumCompany Announcements
Zymeworks Inc Stresses Transparency in Investor Communications
PremiumCompany Announcements
Zymeworks Engages in Key Investor Conferences
Bulls Say, Bears Say
Bulls Say
Financial StabilityWith a strong cash reserve, the company is well-positioned to sustain operations and invest in future growth.
Market ExpansionThe company's potential entry into the autoimmune disease market represents a significant opportunity for growth and diversification.
Pipeline DevelopmentManagement has confirmed plans for new drug submissions, indicating a robust and advancing pipeline.
Bears Say
Clinical TrialsDevelopment of zanidatamab zovodotin has been paused due to competitive developments and management prioritization.
EarningsZymeworks recorded a net loss of $0.42 per share—wider than the forecasted net loss.
Investor SentimentShares are down due to few clinical catalysts in the pipeline and potential market opportunity concerns for zanidatamab.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ZYME FAQ
What was Zymeworks Inc’s price range in the past 12 months?
Zymeworks Inc lowest stock price was $6.01 and its highest was $13.14 in the past 12 months.
What is Zymeworks Inc’s market cap?
Currently, no data Available
When is Zymeworks Inc’s upcoming earnings report date?
Zymeworks Inc’s upcoming earnings report date is Aug 01, 2024 which is in 80 days.
How were Zymeworks Inc’s earnings last quarter?
Zymeworks Inc released its earnings results on May 02, 2024. The company reported -$0.42 earnings per share for the quarter, missing the consensus estimate of -$0.322 by -$0.098.
Is Zymeworks Inc overvalued?
According to Wall Street analysts Zymeworks Inc’s price is currently Undervalued.
Does Zymeworks Inc pay dividends?
Zymeworks Inc does not currently pay dividends.
What is Zymeworks Inc’s EPS estimate?
Zymeworks Inc’s EPS estimate is -$0.42.
How many shares outstanding does Zymeworks Inc have?
Zymeworks Inc has 70,704,890 shares outstanding.
What happened to Zymeworks Inc’s price movement after its last earnings report?
Zymeworks Inc reported an EPS of -$0.42 in its last earnings report, missing expectations of -$0.322. Following the earnings report the stock price went up 2.222%.
Which hedge fund is a major shareholder of Zymeworks Inc?
Among the largest hedge funds holding Zymeworks Inc’s share is Farallon Capital Management, L.L.C.. It holds Zymeworks Inc’s shares valued at 18M.
---
Zymeworks Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.93 (50.76% Upside)
$13.93 (50.76% Upside)
Blogger Sentiment
Bullish
ZYME Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 685.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.08%
12-Months-Change
Fundamentals
Return on Equity
-27.64%
Trailing 12-Months
Asset Growth
-7.82%
Trailing 12-Months
Company Description
Zymeworks Inc
Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani, and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.
---
ZYME Company Deck
---
ZYME Earnings Call
Q1 2024
0:00 / 0:00
---
ZYME Stock 12 Month Forecast
Average Price Target
$13.93
▲(50.76% Upside)
Technical Analysis
Best Analysts Covering ZYME
1 Year
1 Year Success Rate
10/14 ratings generated profit
1 Year Average Return
+36.83%
reiterated a buy rating 11 days ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +36.83% per trade.
---